Prof Martin Wermke talks to ecancer about data he presented at ESMO 2025 from the phase Ib DeLLphi-303 study.

This added DLL3-targeted bispecific T-cell engager tarlatamab to first-line platinum-etoposide plus anti–PD-L1 therapy, demonstrating a manageable safety profile and encouraging early survival outcomes in patients with extensive-stage small cell lung cancer 

Among 96 participants, dose-limiting toxicities occurred in 3%, and the most common treatment-related adverse events were cytokine release syndrome (56%), anaemia (54%), and dysgeusia (46%). 

The objective response rate after tarlatamab addition was 71%, with a median duration of response of 11 months, median progression-free survival of 9 months, and 12-month overall survival of 81%. 

Dr Wermke concludes by commenting on the future potential of tarlatamab and looks to the continued evaluation of the regimen in the phase III DeLLphi-312 trial.